CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trial An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Select Drug-Drug Interactions With Direct Oral Anticoagulants Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation The mSToPS Randomized Clinical Trial Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management Generalizing Intensive Blood Pressure Treatment to Adults With Diabetes Mellitus Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock

Review Article2017 Aug 1;70(5):590-606.

JOURNAL:J Am Coll Cardiol. Article Link

Translational Perspective on Epigenetics in Cardiovascular Disease

van der Harst P, de Windt LJ, Chambers JC Keywords: EWAS; HAT; HDAC; RNA; histones; methylation

ABSTRACT

A plethora of environmental and behavioral factors interact, resulting in changes in gene expression and providing a basis for the development and progression of cardiovascular diseases. Heterogeneity in gene expression responses among cells and individuals involves epigenetic mechanisms. Advancing technology allowing genome-scale interrogation of epigenetic marks provides a rapidly expanding view of the complexity and diversity of the epigenome. In this review, the authors discuss the expanding landscape of epigenetic modifications and highlight their importance for future understanding of disease. The epigenome provides a mechanistic link between environmental exposures and gene expression profiles ultimately leading to disease. The authors discuss the current evidence for transgenerational epigenetic inheritance and summarize the data linking epigenetics to cardiovascular disease. Furthermore, the potential targets provided by the epigenome for the development of future diagnostics, preventive strategies, and therapy for cardiovascular disease are reviewed. Finally, the authors provide some suggestions for future directions.